SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Surgalign Holdings, Inc. (SRGA) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+1813.6%).
- Analyst consensus target $3.50 (+1813.6% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 49/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — SRGA
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.01
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-8.33
Book Value / Share$0.00
Revenue / Share$12.51
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$3.50 (+1813.6%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2013 |
$-0.32 |
$197.98M |
$-17.81M |
-9% |
| 2014 |
$0.05 |
$262.81M |
$2.7M |
1% |
| 2015 |
$0.25 |
$282.29M |
$14.92M |
5.3% |
| 2016 |
$-0.25 |
$272.87M |
$-14.4M |
-5.3% |
| 2017 |
$0.10 |
$279.56M |
$6.27M |
2.2% |
| 2018 |
$-0.02 |
$280.86M |
$-1.25M |
-0.4% |
| 2019 |
$-106.39 |
$117.42M |
$-248.78M |
-211.9% |
| 2020 |
$-78.30 |
$101.75M |
$-194.2M |
-190.9% |
| 2021 |
$-30.08 |
$90.5M |
$-122.91M |
-135.8% |
| 2022 |
$-8.33 |
$81.98M |
$-54.61M |
-66.6% |
